We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Teva Pharmaceutical Industries (TEVA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Teva Pharmaceutical Industries is one of 888 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. TEVA is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for TEVA's full-year earnings has moved 0.25% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, TEVA has gained about 14.80% so far this year. At the same time, Medical stocks have lost an average of 4.10%. This means that Teva Pharmaceutical Industries is outperforming the sector as a whole this year.
Breaking things down more, TEVA is a member of the Medical - Generic Drugs industry, which includes 24 individual companies and currently sits at #25 in the Zacks Industry Rank. Stocks in this group have lost about 10.15% so far this year, so TEVA is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to TEVA as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Teva Pharmaceutical Industries (TEVA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Teva Pharmaceutical Industries is one of 888 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. TEVA is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for TEVA's full-year earnings has moved 0.25% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, TEVA has gained about 14.80% so far this year. At the same time, Medical stocks have lost an average of 4.10%. This means that Teva Pharmaceutical Industries is outperforming the sector as a whole this year.
Breaking things down more, TEVA is a member of the Medical - Generic Drugs industry, which includes 24 individual companies and currently sits at #25 in the Zacks Industry Rank. Stocks in this group have lost about 10.15% so far this year, so TEVA is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to TEVA as it looks to continue its solid performance.